Europe has emerged as a major genomics market and technological leader as a result of programmes like the 1+ Million Genomes, top-tier academic and public research funding, as well as extensive regulatory and clinical applications. MGI Tech Co., Ltd. (or its affiliates, referred to as “MGI”) is committed to improving access throughout the continent and has made a commitment to developing the fundamental tools and technologies to lead life science.
MGI increased its market share in Europe by launching the newest HotMPS* sequencing chemical in a few countries in April of last year. In July and September, respectively, it was subsequently made commercially available in Germany and the United Kingdom. Stronger signal and fewer systematic sequence-based mistakes are two of the major benefits of HotMPS, which is based on the combinatorial Probe Anchor Synthesis (cPAS) technology found in MGI’s DNBSEQTM technology. Soon after that, in July, a new central office was established in Wehrheim, Germany, and in October, MGI opened its first overseas Customer Experience Center (CEC) in Latvia. Two more CECs followed in November, one each in London and Berlin. According to Dr. Yong Hou, general manager of MGI Europe and Africa, “MGI’s newest product roll-out and expansion in Europe highlight our dedication to and staying power in the market.” “We are establishing tighter relationships with consumers and partners, facilitating better understanding and awareness of our goods, and providing the right to another choice as we continue to introduce our proven technology and its benefits to more people in the region.”

Source: Prnewswire